WELLBUTRIN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
4/8 — Partial
Priority Review
WELLBUTRIN by GSK is mechanisms. Approved for major depressive disorder (mdd), defined by the diagnostic, statistical manual (dsm). First approved in 1985.
Drug data last refreshed 23h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WELLBUTRIN is an oral small-molecule antidepressant approved in 1985, currently approaching loss of exclusivity. The drug's mechanism of action and specific indications are not detailed in available data, but it remains a foundational treatment in mental health therapeutics.
LOE Approaching
As LOE approaches, the WELLBUTRIN brand team will transition from growth-focused work to lifecycle management and potential generic defense strategies, likely resulting in smaller commercial teams.
Mechanism of Action
mechanisms. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit the reuptake of serotonin. Bupropion does not inhibit monoamine oxidase.
Indications (3)
Worked on WELLBUTRIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.